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Musculoskeletal tissue repair still represents a challenge in
orthopaedics. Stem cell-based regenerative therapies have
been widely explored using a variety of approaches, from tar-
geted delivery of stem cells and their derivatives to advanced
manufacturing of tissue grafts. Although several studies sup-
port the potential of stem cells in musculoskeletal tissue
repair, few approaches have been successfully translated into
clinics, attributable in part to a lack of well-defined standards
of care in preclinical and clinical studies. This translational
delay also depends on the intrinsic variability and complexity
of the regulatory and legal frameworks worldwide. Stem cell
therapy-based strategies vary significantly depending on the
nature of the musculoskeletal damage to be restored. While
tissue engineering approaches localize stem cells at the site
of injury through biomaterials able to create a proregenera-
tive environment, the use of free cells or their derivatives
(e.g., secretome, microvesicles, and exosomes) requires lim-
ited manipulation and lower processing costs compared to
tissue engineering.
This special issue presents the recent advances in the pre-
clinical and clinical use of mesenchymal stem cells (MSCs) or
their derivatives (e.g., bone marrow aspirate concentrate,
known as BMAC, secretome) for a better understanding of
their therapeutic impact.
In this special issue, the manuscript by C. Centeno et al.
reports the results of a randomized controlled trial on 25
patients of the treatment of partial to full-thickness supraspi-
natus tendon tears by BMAC and platelet products as inject-
able regenerative therapies. Patients reported a mean 89%
improvement at 24 months, with sustained functional gains,
pain reduction, and a size decrease of most tears post-BMAC
treatment, suggesting that BMAC injections are a safe and
useful alternative to conservative exercise therapy in rotator
cuff tears. In their systematic meta-analysis, S. Palombella
et al. assessed the current clinical evidence for the efficacy
of bone marrow-derived cell-based approaches associated
or not with bone scaffolds to treat bone nonunions. Specifi-
cally, in the review, the authors indicate that BMAC or
BMAC/scaffold is the primary choice versus bone marrow-
derived stromal cells (BMSCs) to treat nonunions with a
successful healing at a midterm follow-up (6-12 months).
For the clinical translation of cell-based products, rigid pro-
tocols need to be established. In their work, R. B. Dias et al.
described the manufacture of GMP-grade BMSC in compli-
ance with Brazilian regulatory guidelines for cells intended
for use in humans. Indeed, in vitro-expanded BMSCs have
long been proposed for the treatment of complex bone inju-
ries due to their inherent potential to differentiate into multi-
ple skeletal cell types, modulate inflammatory responses, and
support angiogenesis.
In the field of musculoskeletal tissue repair, nerve injuries
represent a prominent clinical issue. Damaging the connection
betweenmuscle and neural fibers, for example, leads tomuscle
atrophy, with also a known negative impact on the differenti-
ation capacity of the resident tissue-specific progenitor cells. In
their review, Y. Wang et al. focused on the mechanism of
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action, the role and the possible regenerative medicine appli-
cations of Adipose Stem Cells (ASCs) for diseases affecting
the nervous system, overall indicating how these cells can
become one of the most important cell-based tools for the
treatment of neural pathologies in the future.
This special issue also introduces the reader to basic
research aiming at identifying an alternative source of stem
cells with improved differentiative potential into musculoskel-
etal tissues. The study conducted by H. E. Owston et al.
assesses the migration and differentiation properties of
multipotent stromal cells from clinically accessible human
periosteum compared to BMSCs, demonstrating that perios-
teum represents a consistently rich source of highly prolifera-
tive multipotent stromal cells compared to donor-matched
BMSCs with similar osteochondral capacity and lower adipo-
genic potential. In the same line, in their in vivo study, E. R.
Moore et al. highlighted the importance of periosteal Prx1-
expressing cells in contributing to the mechanically induced
bone formation. Interestingly, the authors were able to show
how primary cilia are necessary for a complete mechanical
response of the Prx1-expressing cells, contributing to increase
the knowledge around the role of this, still poorly understood,
cellular organelle during bone (re)generation.
The relevance of the immunomodulatory potential of
stem cells in the treatment of musculoskeletal diseases has
been investigated by M. Viganò et al. The authors proposed
the microfragmented adipose tissue (μFAT) as a convenient
autologous product for the application of MSC-based thera-
pies in clinical settings. In particular, they demonstrated its
efficacy to favor tissue healing in the context of tendon
inflammation, highlighting its capability to counteract the
catabolic and fibrotic response elicited by the proinflamma-
tory interleukin-1 beta (IL-1b) on tendon cells and providing
insights on the mechanism of action of this therapeutic
approach for the treatment of tendon disorders.
The special issue widely reports preclinical studies testing
the efficacy of stem cell-based therapies in animal models and
their relevance with respect to the human pathology in
orthopaedics. In their study, M. Bottagisio et al. demon-
strated the beneficial role of undifferentiated BMSCs loaded
within decellularized xenografts undergoing a stretch-
perfusion culture as an immunomodulatory weapon reduc-
ing the inflammatory process in tendon ruptures. This study
associates the advantages of in vitro expanded and dynami-
cally cultured BMSCs with new biologically relevant bioma-
terials with the potential to promote tendon reconstruction.
In particular, J. Zhang et al. address an important clinical
problem for the restoration of injured musculoskeletal tis-
sues, which is related to the poor intrinsic healing potential
of tendon and ligament tissue. The authors investigated the
influence of Fibroblast Growth Factor-2- (FGF-2-) trans-
fected human amniotic MSCs (hAMSCs) seeded on a human
acellular amniotic membrane scaffold on tendon-to-bone
healing process, using in vitro tests and a rabbit in vivo
model. Their data demonstrate a significantly better healing
of a tendon-to-bone junction, compared to the previously
used biological materials.
Animal models are also a useful tool to investigate the cell
fate/engraftment by tracking imaging in orthopaedics. The
original article by C. Horstmeier et al. investigated in vivo
the magic angle imaging technique to track ASCs labelled
with superparamagnetic iron oxide particles (SPIO) and to
discriminate SPIO-induced artefacts from the surrounding
tendon tissue in equine digital flexor tendons.
Overall, in this research topic, we wanted to underline the
importance of verifying the safety and efficacy of stem cell-
based approaches, as well as the development of relevant
preclinical studies, both in vitro and in vivo. Moreover, a
multidisciplinary approach is required to better elucidate
the mechanisms of stem cell differentiation, function, and
tissue healing. Even more importantly, a good design of
clinical trials should be implemented for the final validation
of stem cell-based therapies in orthopaedics.
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